Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is
the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also …

Nucleos (t) ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …

Background Finite nucleos (t) ide analogue (NUC) therapy has been proposed as an
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …

Background & Aims Flares after nucleos (t) ide analogue (NA) cessation are common and
potentially harmful. Predictors of flares are required for risk stratification and to guide off …

Background & Aims Antivirals represent the mainstay of chronic hepatitis B treatment given
their efficacy and tolerability, but rates of functional cure remain low during long-term …

The majority of chronic viral hepatitis cases are induced via infection with the hepatitis B
virus (HBV), hepatitis C virus (HCV), or hepatitis D virus (HDV). These patients are at …

Background Stop** nucleos (t) ide analogue (NA) therapy in patients with chronic
hepatitis B (CHB) may trigger a beneficial immune response leading to HBsAg loss, but …

Background & Aims Factors predicting HBsAg seroclearance after treatment cessation,
irrespective of nucleos (t) ide analogue (NA) resumption, have important clinical …

Introduction Nucleos (t) ide analogues (NAs) are effective in suppressing the replication of
the hepatitis B virus. However, NAs cannot effectively induce hepatitis B surface antigen …

In recent decades, microRNAs (miRNAs) have emerged as key regulators of gene
expression, and the identification of viral miRNAs (v-miRNAs) within some viruses, including …